IL-18 is produced by prostate cancer cells and secreted in response to interferons

International Journal of Cancer

Volumn 106, Issue 6, 2003, Pages 827-835

  Lebel Binay, Sophie ^a,b   Thiounn, Nicolas ^c   De Pinieux, Gonzague ^c   Vieillefond, Annick ^c   Debré, Bernard ^c   Bonnefoy, Jean Yves ^b   Fridman, Wolf Herman ^a,d   Pagès, Franck ^a,d  

^a INSERM   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c AP HP ^*  (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Caspase 1; IFN ; IFN ; IL 18; Prognosis; Prostate cancer

Indexed keywords

ALPHA INTERFERON; ANTIGEN P24; CASPASE 1 INHIBITOR; CASPASE INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; PEPTIDE; TETRAZOLIUM; TYROSYLVALYLALANYLASPARTALDEHYDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; MICROENVIRONMENT; MOUSE; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; TUMOR CELL LINE; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS; CASPASE 1; CELL DIVISION; COHORT STUDIES; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-18; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0041837658     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11285     Document Type: Article

References (51)

1. Okamura H, Nagata K, Komatsu T, Tanimoto T, Nukata Y, Tanabe F, Akita K, Torigoe K, Okura T, Fukuda S, Kurimoto M. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995;63:3966-72.
2. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Kurimoto M. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
3. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996;156:4274-9.
4. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997;275:206-9.
5. Pages F, Lazar V, Berger A, Danel C, Lebel-Binay S, Zinzindohoue F, Desreumaux P, Cellier C, Thiounn N, Bellet D, Cugnenc PH, Fridman WH. Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions. Eur Cytokine Netw 2001;12:97-104.
6. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997;7: 571-81.
7. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9:143-50.
8. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996;173: 230-5.
9. Tsutsui H, Matsui K, Kawada N, Hyodo Y, Hayashi N, Okamura H, Higashino K, Nakanishi K. IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997;159:3961-7.
10. Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA. Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J Infect Dis 1998;178:1830-4.
11. + human blood mononuclear cells. J Clin Invest 1998;101:711-21.
12. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999; 162:4511-20.
13. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Kurimoto M. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997;43:361-7.
14. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 1998;160:1742-9.
15. Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, Yamamoto H, Kouzu T, Asano T, Ochiai T, Sakiyama S, Tagawa M. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 2000;7:247-54.
16. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999;163:583-9.
17. Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res 2000;60:4838-44.
18. Coughlin C, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox, JC, Trinchieri G, Lee WM. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-52.
19. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH, Fridman WH. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 1999;84:326-30.
20. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 2000;60:3904-8.
21. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7.
22. Royuela M, de Miguel MP, Ruiz A, Fraile B, Arenas MI, Romo E, Paniagua R. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw 2000; 11:119-27.
23. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 2002;99:2830-5.
24. De Pinieux G, Flam T, Zerbib M, Taupin P, Bellahcene A, Waltregny D, Vieillefond A, Poupon MF. Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J Urol 2001;166:1924-30.
25. Kikkawa S, Shida K, Okamura H, Begum NA, Matsumoto M, Tsuji S, Nomura M, Suzuki Y, Toyoshima K, Seya T. A comparative analysis of the antigenic, structural, and functional properties of three different preparations of recombinant human interleukin-18. J Interferon Cytokine Res 2000;20:179-85.
26. Kim EJ, Lee JM, Namkoong SE, Um SJ, Park JS. Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 2002;85:369-80.
27. Shin EC, Ahn JM, Kim CH, Choi Y, Ahn YS, Kim H, Kim SJ, Park JH. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer 2001;93:262-8.
28. Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR, Kiefer MC. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997;272:16351-7.
29. Park H, Byun D, Kim TS, Kim YI, Kang JS, Hahm ES, Kim SH, Lee WJ, Song HK, Yoon DY, Kang CJ, Lee C, et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 2001;79:215-9.
30. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, Canevari S, Ferrini S. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 2002;98:873-8.
31. Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, Kawabe K. Immunohistochemical study of Fas, Fas ligand and interleukin-1beta converting enzyme expression in human prostatic cancer. BJU Int 1998; 81:852-5.
32. Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 2001;61:1227-32.
33. WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer 1998;77:138-45.
34. Nakajima Y, DelliPizzi A, Mallouh C, Ferreri NR. Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines. Urol Res 1995;23:205-10.
35. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
36. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after cas tration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5: 2891-8.
37. Bruckheimer EM, Kyprianou N. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate 2002;53:133-42.
38. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 2000;60:3904-8.
39. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997;33:233-9.
40. Cho D, Song H, Kim YM, Houh D, Hur DY, Park H, Yoon D, Pyun KH, Lee WJ, Kurimoto M, Kim YB, Kim YS, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000;60:2703-9.
41. Pages F, Vives V, Sautes-Fridman C, Fossiez F, Berger A, Cugnenc PH, Tartour E, Fridman WH. Control of tumor development by intratumoral cytokines. Immunol Lett 1999;68:135-9.
42. Tartour E, Gey A, Sastre-Garau X, Lombard Surin I, Mosseri V, Fridman WH. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst 1998;90:287-94.
43. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999;162:5070-7.
44. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191:239-44.
45. Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000;18:135-46.
46. Lauri D, Bertomeu MC, Orr FW, Bastida E, Sauder D, Buchanan MR. Interleukin-1 increases tumor cell adhesion to endothelial cells through an RGD dependent mechanism: in vitro and in vivo studies. Clin Exp Metastasis 1990;8:27-32.
47. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 1993;177:1391-8.
48. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000;97:734-9.
49. Mendoza L, Carrascal T, De Luca M, Fuentes AM, Salado C, Blanco J, Vidal-Vanaclocha F. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukin-18-activated hepatic sinusoidal endothelium: implications for circulating cancer cell arrest in the murine liver. Hepatology 2001;34:298-310.
50. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 2001;92:2050-5.
51. Gunel N, Coskun U, Sancak B, Gunel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 2002;95:663-7.